Hope for RVCL: experimental drug tested in tiny trial
NCT ID NCT04611880
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested the drug crizanlizumab in 18 people with RVCL, a rare and fatal genetic condition that damages small blood vessels in the brain and eyes. There is currently no treatment for RVCL. The study measured changes in brain lesions on MRI scans to see if the drug could slow the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- crizanlizumab (Adakveo)
- What this could lead to
- If it works, this could point toward a treatment for RVCL, a rare and fatal disease with no current options.
- What could go wrong
- This is a very small early-phase trial (18 people) with no control group, so results may not be conclusive. The drug may not slow the disease or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RVCL - RETINAL VASCULOPATHY CEREBRAL LEUKOENCEPHALOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Andria Ford
St Louis, Missouri, 63110, United States
-
Perelman School of Medicine; University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States